What is INT230-6?
The study drug is a multi-agent (more than one medication) formulated drug product specifically designed to be directly injected into tumors. The first two medications are agents that normally are given into the veins (intravenously) during chemotherapy: Cisplatin and Vinblastine Sulfate. The third ingredient is a penetration enhancer. This compound allows the first two ingredients to disperse throughout the tumor and move directly into the cancer cells themselves.
How is the new drug used?
The study medication will be injected directly into your tumor(s). You will be assigned to a cycle that is either approximately 28-days long for cohorts A, B, C, D for a total of 5 monthly cycles or 14 days long for 5 two-week cycles or about 2 months. Your study doctor will inform you what dose you will be receiving.